| P50 | author | Xuebin B. Yang | Q47170686 |
| | Peter Giannoudis | Q47486820 |
| P2093 | author name string | Xiaodong Jia | |
| | Paul V Hatton | |
| | Elizabeth R Kapasa | |
| P2860 | cites work | Biology of RANK, RANKL, and osteoprotegerin | Q21195419 |
| | The Modulatory Effects of Mesenchymal Stem Cells on Osteoclastogenesis | Q26773017 |
| | Surface Modifications and Their Effects on Titanium Dental Implants | Q26782133 |
| | Osteoimmunology: Major and Costimulatory Pathway Expression Associated with Chronic Inflammatory Induced Bone Loss | Q27008993 |
| | Evidence for osteocyte regulation of bone homeostasis through RANKL expression | Q28247757 |
| | Osteoclast differentiation and activation | Q29547556 |
| | Surface modification of biomedical and dental implants and the processes of inflammation, wound healing and bone formation | Q33649253 |
| | Osteoprotegerin ligand: a regulator of immune responses and bone physiology. | Q34079327 |
| | Denosumab and bisphosphonates: different mechanisms of action and effects. | Q34154083 |
| | The osteoclastogenic molecules RANKL and RANK are associated with periprosthetic osteolysis | Q34346237 |
| | Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection | Q35008871 |
| | The biology of fracture healing | Q35017085 |
| | Molecular mechanisms controlling bone formation during fracture healing and distraction osteogenesis | Q35029178 |
| | Influences of IL-6R antibody on PMMA bone cement-mediated expression of OPG and RANKL in synovial fibroblasts | Q35142150 |
| | Titanium uptake, induction of RANK-L expression, and enhanced proliferation of human T-lymphocytes | Q84655259 |
| | Denosumab-related osteonecrosis of the jaw | Q84920561 |
| | Loss of osteocyte integrity in association with microdamage and bone remodeling after fatigue in vivo. | Q50514494 |
| | Biocorrosion and uptake of titanium by human osteoclasts. | Q50540398 |
| | Risk of osteonecrosis of the jaw in cancer patients receiving denosumab: a meta-analysis of seven randomized controlled trials. | Q51054919 |
| | The correlation of RANK, RANKL and TNFalpha expression with bone loss volume and polyethylene wear debris around hip implants. | Q51171484 |
| | Response of the osteocyte syncytium adjacent to and distant from linear microcracks during adaptation to cyclic fatigue loading. | Q52560332 |
| | Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. | Q53897603 |
| | Two distinct cellular mechanisms of osteoclast formation and bone resorption in periprosthetic osteolysis. | Q53945794 |
| | Pressure-induced periprosthetic osteolysis: a rat model | Q74151112 |
| | Factors regulating osteoclast formation in human tissues adjacent to peri-implant bone loss: expression of receptor activator NFkappaB, RANK ligand and osteoprotegerin | Q79273226 |
| | Microstimulation at the bone-implant interface upregulates osteoclast activation pathways | Q79842637 |
| | Serum interleukin-6 as a marker of periprosthetic infection following total hip and knee arthroplasty | Q81158507 |
| | Titanium nitride oxide coating on rough titanium stimulates the proliferation of human primary osteoblasts | Q82503402 |
| | Bio-corrosion of stainless steel by osteoclasts--in vitro evidence | Q83071307 |
| | Over-expression of receptor activator of nuclear factor-kappaB ligand (RANKL), inflammatory cytokines, and chemokines in periprosthetic osteolysis of loosened total hip arthroplasty | Q84587984 |
| | Biological response to prosthetic debris | Q35188740 |
| | Understanding peri-implant endosseous healing. | Q35213218 |
| | Regulation of osteoclast activity in peri-implant tissues | Q35756689 |
| | The role of macrophages in osteolysis of total joint replacement | Q35913643 |
| | The molecular triad OPG/RANK/RANKL: involvement in the orchestration of pathophysiological bone remodeling | Q35961678 |
| | Chondrocytes-Specific Expression of Osteoprotegerin Modulates Osteoclast Formation in Metaphyseal Bone | Q36017881 |
| | Bone lysis and inflammation | Q36031336 |
| | Current concepts of molecular aspects of bone healing | Q36231316 |
| | Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength | Q36269835 |
| | Functions of RANKL/RANK/OPG in bone modeling and remodeling | Q36700779 |
| | Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease. | Q36860987 |
| | RANK, RANKL and osteoprotegerin in bone biology and disease. | Q37199218 |
| | Inflammation and bone loss in periodontal disease | Q37232619 |
| | The Role of Inflammatory Cytokines, the RANKL/OPG Axis, and the Immunoskeletal Interface in Physiological Bone Turnover and Osteoporosis | Q37287589 |
| | RANK/RANKL: regulators of immune responses and bone physiology | Q37348448 |
| | Metal is not inert: role of metal ions released by biocorrosion in aseptic loosening--current concepts | Q37617219 |
| | Bone fracture and bone fracture repair | Q37869386 |
| | Use of bisphosphonates in orthopedic surgery: pearls and pitfalls | Q38224315 |
| | Enzymatically synthesized inorganic polymers as morphogenetically active bone scaffolds: application in regenerative medicine | Q38265746 |
| | Predictors of and outcomes following orthopaedic joint surgery in patients with early rheumatoid arthritis followed for 20 years | Q38683116 |
| | The role of biosilica in the osteoprotegerin/RANKL ratio in human osteoblast-like cells | Q39673457 |
| | Osteoblast proliferation and maturation by bisphosphonates | Q40573161 |
| | Bone cement extracts modulate the osteoprotegerin/osteoprotegerin-ligand expression in MG63 osteoblast-like cells | Q40731842 |
| | Macrophage colony-stimulating factor and interleukin-6 release by periprosthetic cells stimulates osteoclast formation and bone resorption. | Q40916935 |
| | Mechanisms regulating increased production of osteoprotegerin by osteoblasts cultured on microstructured titanium surfaces | Q42033564 |
| | Expression of osteoprotegerin, receptor activator of NF-kappaB ligand (osteoprotegerin ligand) and related proinflammatory cytokines during fracture healing. | Q42505465 |
| | Osteonecrosis of the jaws induced by anti-RANK ligand therapy | Q43259728 |
| | The effect of a single dose of osteoprotegerin in postmenopausal women | Q43520860 |
| | Oral pentoxifylline inhibits release of tumor necrosis factor-alpha from human peripheral blood monocytes : a potential treatment for aseptic loosening of total joint components. | Q43672999 |
| | Expression of inflammatory cytokines, RANKL and OPG induced by titanium, cobalt-chromium and polyethylene particles | Q44141561 |
| | Differential expression of RANKL and osteoprotegerin in gingival crevicular fluid of patients with periodontitis | Q47243804 |
| | The influence of wear particles in the expression of osteoclastogenesis factors by osteoblasts | Q47407989 |
| | Prostaglandin E2, interleukin 1alpha, and tumor necrosis factor-alpha increase human osteoclast formation and bone resorption in vitro | Q47914319 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 4 | |
| P577 | publication date | 2017-09-22 | |
| P1433 | published in | Journal of Functional Biomaterials | Q27723881 |
| P1476 | title | The Effect of RANKL/OPG Balance on Reducing Implant Complications | |
| P478 | volume | 8 | |